hre 664 has been researched along with imipenem, anhydrous in 1 studies
| Studies (hre 664) | Trials (hre 664) | Recent Studies (post-2010) (hre 664) | Studies (imipenem, anhydrous) | Trials (imipenem, anhydrous) | Recent Studies (post-2010) (imipenem, anhydrous) |
|---|---|---|---|---|---|
| 8 | 0 | 0 | 4,784 | 391 | 1,397 |
| Protein | Taxonomy | hre 664 (IC50) | imipenem, anhydrous (IC50) |
|---|---|---|---|
| Beta-lactamase | Pseudomonas aeruginosa | 0.15 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bauernfeind, A; Jungwirth, R; Schweighart, S | 1 |
1 other study(ies) available for hre 664 and imipenem, anhydrous
| Article | Year |
|---|---|
In-vitro activity of meropenem imipenem, the penem HRE 664 and ceftazidine against clinical isolates from West Germany.
Topics: Anti-Bacterial Agents; Bacteria; Bacteria, Anaerobic; Bacterial Infections; Carbapenems; Ceftazidime; Culture Media; Enterobacteriaceae; Germany, West; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Lactams; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 1989 |